Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 29,611 shares at $108.56 ($3.2M) on 2024-04-10, disclosed to the SEC on 2024-04-12.
Scheduled sale ($3.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $106.59 | 6,351 | $677K | 21.3% |
| 2 | $106.59 | 6,351 | $677K | 21.3% |
| 3 | $107.31 | 7,512 | $806K | 25.4% |
| 4 | $107.31 | 7,512 | $806K | 25.4% |
| 5 | $108.56 | 748 | $81K | 2.6% |
| 6 | $108.56 | 748 |
| $81K |
| 2.6% |
| 7 | $109.36 | 389 | $43K | 1.3% |
| Total | $107.09 avg | 29,611 | $3.2M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |